News & Events

Extranet


FP7
HIVINNOV (Grant n°305137) is a collaborative research project supported by the European Union


FDA Approves ViiV HIV Integrase Inhibitor Dolutegravir

August 12th 2013

 

The U.S. Food and Drug Administration (FDA) today (August 12, 2013) approved the second HIV integrase inhibitor, dolutegravir, which will be marketed under the brand name Tivicay by ViiV Healthcare. Phase 3 studies showed that dolutegravir works as well as raltegravir (Isentress) or Atripla and is generally safe and well-tolerated.

 

Read more...